Literature DB >> 26124315

CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series.

Ariz Akhter1, Etienne Mahe2, Lesley Street3, Payam Pournazari1, Marco Perizzolo4, Meer-Taher Shabani-Rad1, Douglas A Stewart3, Adnan Mansoor1.   

Abstract

BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive disease with genetic heterogeneity and discrete clinical subtypes. MCL is rarely CD10 positive. These cases raise the question whether a subset of MCL may be germinal centre (GC) derived, and have distinct clinicopathological characteristics. AIMS AND METHODS: A series of nine CD10-positive MCL cases is described herein. The clinicopathological and immunophenotypic features, immunoglobulin somatic hypermutation (SHM) status and gene expression profile (GEP) data are detailed. These features were compared with two independent sets (n=20, each) of CD10-negative MCL cases (controls), which were randomly selected from our institutional registry.
RESULTS: GEP showed distinct expression of a GC signature in CD10-positive MCL cases with minimal impact on downstream signalling pathways. There were no significant differences in the clinicopathological features or clinical outcome between our CD10-positive and CD10-negative MCL cases. The frequency of SHM was comparable with established data.
CONCLUSIONS: This study provides convincing evidence that CD10 expression is related to a distinct GC signature in MCL cases, but without clinical or biological implications. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  IMMUNOCYTOCHEMISTRY; LYMPHOMA; MOLECULAR PATHOLOGY; TUMOUR BIOLOGY

Mesh:

Substances:

Year:  2015        PMID: 26124315     DOI: 10.1136/jclinpath-2015-202955

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

Review 1.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

Review 2.  The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.

Authors:  Richard Arkwright; Tri Minh Pham; Jeffrey A Zonder; Q Ping Dou
Journal:  Expert Opin Drug Discov       Date:  2016-12-20       Impact factor: 6.098

3.  Cooccurrence of CD10-Positive and CD10-Negative Mantle Cell Lymphoma Complicated With Central Nervous System Involvement Solely by CD10-Positive Population.

Authors:  Noriyasu Fukushima; Tatsuji Mino; Koji Arihiro; Tatsuo Ichinohe
Journal:  Cureus       Date:  2022-01-17

Review 4.  Clinicopathologic Features and Treatment of CD10-Positive Mantle Cell Lymphoma: A Case Report and Review of Literature.

Authors:  Christopher Hino; Bryan Pham; Austin L Gray; Jun Wang; Dan Ran Castillo; Mojtaba Akhtari; Yan Liu
Journal:  Pathol Oncol Res       Date:  2022-08-25       Impact factor: 2.874

Review 5.  The pathologic diagnosis of mantle cell lymphoma.

Authors:  Shaoying Li; Jie Xu; M James You
Journal:  Histol Histopathol       Date:  2021-06-11       Impact factor: 2.303

Review 6.  New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015-September 2015.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2015-11-19       Impact factor: 0.196

7.  CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases.

Authors:  Jie Xu; L Jeffrey Medeiros; Annapurna Saksena; Michael Wang; Jiehao Zhou; Jingyi Li; C Cameron Yin; Guilin Tang; Lifu Wang; Pei Lin; Shaoying Li
Journal:  Oncotarget       Date:  2017-12-15

8.  Clinical and biological features of mantle cell lymphoma patients with co-expression of CD10 and BCL-6: a retrospective study.

Authors:  Wanzi Chen; Hangmin Liu; Pengcheng Wang; Guoping Li
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.